Playing the long game: will the ongoing evolution of the psoriasis market play out in atopic dermatitis?
With several advanced therapy options now available to treat moderate-severe atopic dermatitis - and more on the horizon - how is the treatment landscape changing? Can we use evolutions in psoriasis treatment as a proxy, and can we draw any parallels between physicians’ therapeutic goals?
In a follow-up edition to our 2019 point of view The Biologic Blueprint, we use Ipsos’ syndicated Atopic Dermatitis and Psoriasis Therapy Monitor data to compare developments across the two indications now additional advanced therapy options are available, and how physicians’ treatment goals and expectations are evolving in tandem.
Download
